Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
NCT ID: NCT00028301
Last Updated: 2010-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
2001-02-28
2003-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atazanavir
Lopinavir/Ritonavir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are receiving a PI-containing highly active antiretroviral therapy (HAART) for at least 12 weeks.
* Have a viral load of 1,000 or more copies/ml within 4 weeks of screening and within 4 weeks prior to randomization.
* Have 2 CD4 cell counts of 50 or more cells/mm3 at least 96 hours apart and within 4 weeks before randomization.
* Are at least 16 years old.
* Have a documented virologic response to at least 1 HAART regimen.
* Have phenotypic sensitivity to at least 2 of the following: ddl, d4T, ZDV, 3TC, ABC.
* Have phenotypic sensitivity to atazanavir and LPV/RTV.
* Use effective barrier methods of birth control.
* Will be available for 48 weeks.
Exclusion Criteria
* Have taken 2 or more PIs and had virologic failure.
* Have taken atazanavir or LPV/RTV.
* Have an HIV-related infection (within 30 days) or any medical condition requiring treatment at the time of enrollment.
* Have had acute hepatitis in the 30 days prior to study entry.
* Have received certain drugs within 3 months of study start or expect to need them at time of enrollment.
* Abuse alcohol or drugs in a way that would interfere with the study.
* Have very bad diarrhea within 30 days prior to study entry.
* Are pregnant or breast-feeding.
* Have a history of hemophilia.
* Use lipid-lowering drugs (within the previous 30 days).
* Have cardiomyopathy or symptoms of other heart disease.
* Cannot take medicine by mouth.
* Have any other condition that would interfere with the study.
* Have pancreatitis, if choosing ddI as part of NRTI pair.
* Have bilateral peripheral neuropathy at time of screening, if choosing ddI or or d4T as part of the NRTI pair.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cooper Green Hosp
Birmingham, Alabama, United States
Phoenix Body Positive
Phoenix, Arizona, United States
East Bay AIDS Ctr
Berkeley, California, United States
Saint Francis Mem Hosp / HIV Care Unit
San Francisco, California, United States
Kaiser Foundation Hospital
San Francisco, California, United States
San Francisco Veterans Administration Med Ctr
San Francisco, California, United States
Harbor UCLA Med Ctr
Torrance, California, United States
Beacon Clinic / Boulder Community Hosp
Boulder, Colorado, United States
IDC Research Initiative
Altamonte Springs, Florida, United States
Larry Bush
Atlantis, Florida, United States
Community Health Care
Fort Lauderdale, Florida, United States
South Beach Medical Associates
Miami Beach, Florida, United States
Florida ID Group
Orlando, Florida, United States
Infectious Disease Specialists of Atlanta
Decatur, Georgia, United States
Univ of Hawaii
Honolulu, Hawaii, United States
Sky Blue
Boise, Idaho, United States
Infectious Disease of Indiana
Indianapolis, Indiana, United States
Univ of Kansas School of Medicine
Wichita, Kansas, United States
Univ of Kentucky Med Ctr
Lexington, Kentucky, United States
Community Research Initiative
Brookline, Massachusetts, United States
Univ of Massachusetts
Worcester, Massachusetts, United States
Southampton Healthcare Inc
St Louis, Missouri, United States
Steven Zell
Reno, Nevada, United States
VAMC New Jersey Healthcare System
East Orange, New Jersey, United States
North Jersey Community Research Initiative
Newark, New Jersey, United States
Albany Med College
Albany, New York, United States
Erie County Med Ctr
Buffalo, New York, United States
North Shore Univ Hosp
Manhasset, New York, United States
Community Health Network
Rochester, New York, United States
Jemsek Clinic
Huntersville, North Carolina, United States
Oregon Health Sciences Univ
Portland, Oregon, United States
Research & Education Group
Portland, Oregon, United States
Mark Watkins
Philadelphia, Pennsylvania, United States
Univ of South Carolina School of Medicine
Columbia, South Carolina, United States
North Texas Center for AIDS & Clinical Research
Dallas, Texas, United States
Nicholas Bellos
Dallas, Texas, United States
Houston Clinical Research Network
Houston, Texas, United States
Infectious Diseases Associates of Houston
Houston, Texas, United States
Claudia Rodriguez MD
Buenos Aires, , Argentina
Elida Pallone MD
Buenos Aires, , Argentina
Fundacion Huesped
Buenos Aires, , Argentina
Hospital Italiano
Buenos Aires, , Argentina
CAICI
Rosario Santa Fe, , Argentina
Alfred Hosp
Prahan, , Australia
Prahran Market Clinic
South Yarra, , Australia
Saint Vincent's Hosp Med Centre
Sydney, , Australia
Taylors Square Clinic
Sydney, , Australia
Inst of Tropical Medicine
Antwerp, , Belgium
CHU Saint Pierre
Brussels, , Belgium
Cliniques Universitaires Saint Luc
Brussels, , Belgium
University Hospital Gent
Ghent, , Belgium
Domaine Universitaire Du SART-TILMAN
Liège, , Belgium
Hospital de Clinicas da Universidade Federal do Parana
Curitiba, , Brazil
Hospital Nossa Senhora da Conceicao-GCH
Porto Alegre, , Brazil
Instituto de Infectologia Emilio Ribas
São Paulo, , Brazil
Toronto Hosp
Toronto, Ontario, Canada
Clinique Medicale du Quartier Latin
Montreal, Quebec, Canada
Dr Roger P Leblanc
Montreal, Quebec, Canada
Montreal Gen Hosp / Div of Clin Immuno and Allergy
Montreal, Quebec, Canada
Fundacion Arriaran
Santiago, , Chile
Hosp Sotero de Rio
Santiago, , Chile
Hopital Hotel Dieu de Lyon
Lyon, , France
CHU De Bicetre
Paris, , France
Hopital Cochin - Port Royal
Paris, , France
Services des Maladies Infectieuses
Paris, , France
Hopital Gustave Dron
Tourcoing, , France
Ospedale S Orsola
Bologna, , Italy
Immunoligia Universita Cagliari
Cagliari, , Italy
Reparto di Malattie Infettive
Corso Svizzera, , Italy
Ospedale Luigi Sacco Cargnel
Milan, , Italy
Ospedale S Raffaele
Milan, , Italy
Ospedale degli Infermi
Rimini, , Italy
Cat All Immun Clin
Roma, , Italy
Ospedale Amedeo de Savoia
Torino, , Italy
Ospedale Amedeo di Savoia
Torino, , Italy
Hospital 1 ro de Octubre
Mexico City, , Mexico
Hospital General
Mexico City, , Mexico
Hospital Regional
Mexico City, , Mexico
Instituto Nacional de la Nutricion
Mexico City, , Mexico
Univ Medical Center Utrecht
CX Utrecht, , Netherlands
Hosp Guillermo Almenara-Medicina 1
Lima, , Peru
Hosp Nacional Cayetano Heredia
Lima, , Peru
San Cristobal Hosp
Coto Laurel, Ponce, , Puerto Rico
Clinical Research Puerto Rico Inc
San Juan, , Puerto Rico
Hosp Clinic
Barcelona, , Spain
Hospital Germans Trias I Pujol
Barcelona, , Spain
Hosp de Basurto / Enfermedades Infecciosas
Bilboa, , Spain
Hosp Reina Sofia
Córdoba, , Spain
Hosp Carlos III
Madrid, , Spain
Hosp Ramon y Cajal
Madris, , Spain
Hosp Nuestra Senora de Covadonga
Oviedo, , Spain
Hosp Virgen Del Rocio
Seville, , Spain
Whittal Street Clinic
Birmingham, , United Kingdom
Royal Liverpool Univ Hosp
Liverpool, , United Kingdom
Aurora Hospital
, ,
Department of Infection & Tropical Medicine
, ,
Klinicka Chorobzkaznych AM
, ,
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI424-043
Identifier Type: -
Identifier Source: secondary_id
302D
Identifier Type: -
Identifier Source: org_study_id